Imatinib mesylate (trade name Glivec® or Gleevec) is emerging as an important therapy in
the management of chronic myeloid leukaemia (CML). It is clinically useful to monitor the …

Real‐time quantitative reverse transcription‐polymerase chain reaction (Q‐RT‐PCR) is
increasingly used to monitor responses in chronic myeloid leukaemia (CML). The peripheral …

Real-time quantitative polymerase chain reaction (PCR) for BCR-ABL mRNA in the
peripheral blood (RQ-PCR) provides an accurate and reliable measure of response to …

Although most patients with chronic myeloid leukemia (CML) treated with imatinib mesylate
achieve a complete cytogenetic response (CCR), some patients will relapse. To determine …

Abstract Imatinib mesylate (STI571), a specific Bcr-Abl inhibitor, has shown a potent
antileukemic activity in clinical studies of chronic myeloid leukemia (CML) patients. Early …

Bone marrow BCR‐ABL transcript levels were monitored serially by real‐time quantitative
PCR in 46 imatinib‐treated chronic myeloid leukemia patients after achieving complete …

BACKGROUND AND OBJECTIVES: Imatinib mesylate induces a complete cytogenetic
response (CCR) in many patients with chronic myeloid leukemia (CML). However, the …

The degree of tumor load reduction as measured by cytogenetic response is an important
prognostic factor for chronic myelogenous leukemia (CML) patients on therapy. We sought …

Purpose: The purpose of our investigation was to evaluate the response and minimal
residual disease by quantitative competitive PCR (QC-PCR) studies in patients with chronic …

About 75% of patients with newly diagnosed chronic phase (CP) chronic myeloid leukemia
(CML) treated initially with imatinib achieve complete cytogenetic remission (CCyR), 1 and …